ArticleAntimicrobial agents and chemotherapy2018
Molecular Epidemiology of Emerging
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Molecular analysis of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Clonal Diversity and Resistome Dynamics ofMedicina (Kaunas, Lithuania) · 2025Article
- High Prevalence of Virulence andPathogens (Basel, Switzerland) · 2025Article
- Whole-genome sequencing ofMicrobial genomics · 2025Article
- Molecular epidemiology of carbapenem-resistantmSphere · 2025Article
- Whole genome sequencing insight into carbapenem-resistant and multidrug-resistantMicrobiology spectrum · 2024Article
- Co-evolutionary adaptations ofEvolutionary applications · 2022Article
- Whole-genome analysis of carbapenem-resistantComputational and structural biotechnology journal · 2022Article
- Molecular Epidemiology of Extensively-Drug ResistantInfection and drug resistance · 2021Article
- Prevalence of OXA-Type β-Lactamase Genes among Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2020Article
- The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2020Review
- Emergence, molecular mechanisms and global spread of carbapenem-resistantMicrobial genomics · 2019Review
- Molecular Epidemiology of Emerging Carbapenem Resistance inAntimicrobial agents and chemotherapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rate of recovery of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.